We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Plasma Neurofilament Light Predicts All-Cause Mortality Risk

By LabMedica International staff writers
Posted on 21 Jun 2022

Neurofilament light chain (NfL) is a cytoskeletal protein component exclusively expressed in neurons that is released into the extracellular fluids, including blood, during neuroaxonal damage. More...

NfL is linked to mortality in neurological disorders, remaining unexplored in population studies.

NfL reflects sub-cortical large-caliber axonal degeneration. Plasma NfL levels correlate strongly with cerebrospinal fluid (CSF) NfL levels, adding to its clinical utility in differential diagnoses for dementias and other neurodegenerative diseases. Therefore, plasma NfL measurements are advantageous given the invasiveness of CSF assessments and feasibility for long-term monitoring.

Scientists at the National Institute on Aging (Baltimore, MD, USA) collected longitudinal data from 694 participants in the Healthy Aging in Neighborhoods of Diversity Across the Life Span study (HANDLS, mean age first visit [v1]: 47.8 years, 42% male, 55.8% African American). Fasting blood samples were collected between 9:30 am and 11:30 am into EDTA blood collection tubes.

Plasma NfL was measured prospectively at three visits. Plasma NfL levels were quantified using the Simoa NF-light Advantage Kit on a Simoa HD-X analyzer by Quanterix (Billerica, MA, USA). Total cholesterol (mg/dL), HDL cholesterol (mg/dL), high-sensitivity C-reactive protein (hsCRP) (mg/dL), albumin (g/dL), and glycosylated hemoglobin (HbA1c) (%) were quantified by contract laboratories (Quest Diagnostics, Chantilly, VA, USA). In this study, the δNfL is the annualized rate of change between NfLv1, NfLv2, and NfLv3, on average, when these measurements were Loge-transformed.

The team reported that most notably, men had significantly higher plasma NfL (Loge-transformed) compared to women at both visits 1 and 3. These differences remained comparable after further adjustment for age, race, and poverty status. Moreover, men were more likely than women to be pre-diabetic, with the reverse being observed in the case of diabetes. Self-reported history of cardiovascular disease (CVD) was more prevalent in women (15.9% versus 8.7%). Several continuous components of AL were higher among women, namely hsCRP, total cholesterol, and HDL cholesterol, while the reverse was observed for albumin and diastolic blood pressure (DBP). Similar patterns were observed for binary AL components. Notably, NfLv1 was shown to be a better prognostic indicator at normal hsCRP values among women, while HbA1c and δNfL interacted synergistically to determine mortality risk, overall.

The authors concluded that plasma NfL levels measured both at baseline and over time can predict all-cause mortality in women. The study was published on June 13, 2022 in the journal BMC Medicine.

Related Links:
National Institute on Aging 
Quanterix 
Quest Diagnostics 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
New
Toxoplasma Gondii Test
Toxo IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: A new at-home self-collection device aims to reduce the screening gap for cervical cancer (Photo courtesy of CU School of Medicine)

New At-Home Cervical Cancer Screening Device to Increase Accessibility for Patients

Cervical cancer is typically linked to certain types of human papillomavirus (HPV), which is passed through sexual contact. While many people are infected with HPV, only a small percentage will develop... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.